
each z1 and z2 is independently selected from the group of 0, 1 and 2;
each k1 and k2 is independently selected from the group of 0, 1 and 2;

wherein, in (L-f) w is 1 or 2;

wherein in (L-g)
Z is $CR^{16}R^{17}$ and R^{15} is hydrogen when each x is 0 and y is 1; or
Z is $CR^{16}R^{17}$ and R^{15} is selected from the group consisting of hydrogen, methyl and phenyl when each x is 0 and y is 2; or
(L-g) is (L-g'') when Z is NR^{16} ~~when each x is 1 and y is 1;~~



(L-g'');

wherein R^{16} and R^{17} are each independently selected from the group consisting of hydrogen; unsubstituted phenyl; and phenyl substituted with 1, 2 or 3 halo substituents;

wherein in (L-h),
Q is O or N-R^{18}, wherein R^{18} is selected from hydrogen and C_{1-3}alkyl;

wherein

each Het^1 is a saturated heterocyclic radical selected from pyrrolidinyl; piperidinyl; piperazinyl; and morpholinyl; each of which may be optionally substituted with 1 or 2 substituents independently selected from the group consisting of C_{1-6}alkyl, halo, C_{1-3}alkyl substituted with one or more independently selected halo substituents, unsubstituted phenyl or phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy; and

each Het^2 is an aromatic heterocyclic radical selected from pyridinyl and pyrimidinyl; each of which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of halo; C_{1-3}alkyl; C_{1-3}alkyloxy; and C_{1-3}alkyl substituted with one or more independently selected halo substituents;

each Het^3 is a heterocyclic radical selected from 1,3-thiazolyl optionally substituted with C_{1-3}alkyl; unsubstituted benzofuranyl; unsubstituted 3,4-dihydro-*2H*-chromenyl; and unsubstituted *1H*-indolyl;

each halo is selected from the group consisting of fluoro, chloro, bromo and iodo;


each R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{6a}, R^{6b}, R^{6c} and R^{6d} is independently selected from the group consisting of hydrogen and C_{1-3}alkyl; or $CR^{5b}R^{6b}$ together form a (C=O) or a C_{3-7}cycloalkylidene radical;

each R^{10a}, R^{10b} and R^{10c} is H;

wherein, in (L-e),
when t is 1 or 2, R^{11} is hydrogen and R^{12} is selected from a substituent selected from the group consisting of phenyl, phenyloxy and phenylamino, each of which may be optionally substituted with 1 or 2 halo substituents; or
when t is 1, then $CR^{11}R^{12}$ form a radical of formula (i); wherein
R^{14i} is fluoro;
u1 is 0 or 1;
v1 is 2;
z1 is selected from the group of 1 and 2;
k1 is 0; or
when t is 3, then $CR^{11}R^{12}$ form a radical of formula (i); wherein
R^{14i} is fluoro;
u1 is 0 or 1;
v1 is 0;
z1 is selected from the group of 1 and 2;
k1 is 0;

wherein, in (L-f) w is 1 or 2;

wherein in (L-g)
Z is $CR^{16}R^{17}$ and R^{15} is hydrogen when each x is 0 and y is 1; or
Z is $CR^{16}R^{17}$ and R^{15} is phenyl when each x is 0 and y is 2; or
(L-g) is (L-g'') when Z is NR^{16} ~~when each x is 1 and y is 1;~~



(L-g'');


wherein R^{16} and R^{17} are each independently selected from the group consisting of hydrogen; unsubstituted phenyl; and phenyl substituted with 1, 2 or 3 halo substituents;

wherein in (L-h), Q is O;

each Het^1 is a saturated heterocyclic radical selected from pyrrolidinyl; piperidinyl; piperazinyl; and morpholinyl; each of which is unsubstitued or substituted with 1

wherein, in (L-f) w is 1 or 2;

wherein in (L-g)
Z is $CR^{16}R^{17}$ and R^{15} is hydrogen when each x is 0 and y is 1; or
Z is $CR^{16}R^{17}$ and R^{15} is phenyl when each x is 0 and y is 2; or
(L-g) is (L-g'') when Z is NR^{16} ~~when each x is 1 and y is 1;~~



(L-g");

wherein R^{16} and R^{17} are each independently selected from the group consisting of hydrogen; unsubstituted phenyl; and phenyl substituted with 1 or 2 halo substituents;


wherein in (L-h), Q is O;
each halo is selected from the group consisting of fluoro, chloro and bromo;
and the pharmaceutically acceptable salts and the solvates thereof.

In an embodiment, the invention relates to compounds of Formula (I) and stereochemically isomeric forms thereof, wherein

n is selected from 0 and 1;
m is 0 or 1;
R is methyl;
R^1 is selected from the group consisting of C_{1-6}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; (C_{1-3}alkyloxy)C_{1-3}alkyl; and (C_{3-7}cycloalkyl)C_{1-3}alkyl;
R^2 is selected from halo; cyano; C_{1-3}alkyl; and C_{1-3}alkyl substituted with one or more independently selected halo substituents;
(L) is selected from (L-a); (L-b); and (L-g) wherein
R^{3a} is selected from the group consisting of unsubstituted phenyl; phenyl substituted with 1 or 2 independently selected halo substituents; pyridinyl; pyridinyl substituted with 1 or 2 halo substituents; pyrimidinyl; and pyrimidinyl substituted with 1 or 2 independently selected halo substituents;
R^{4a} is selected from hydrogen; halo; C_{1-3}alkyl; and trifluoromethyl;
or $CR^{3a}R^{4a}$ forms a radical of formula (d); wherein
W^{1d} is CH;
R^{7d} and R^{8d} are both methyl;
R^{9d} is fluoro;
q1 is 1;

CLAIMS

1. A compound of formula (I)



(I)

or a stereochemically isomeric form thereof

wherein

n is selected from the group consisting of 0, 1 and 2;


m is selected from the group consisting of 0, 1, and 2;

R is selected from methyl or trifluoromethyl;


R^1 is selected from the group consisting of hydrogen; C_{1-6}alkyl; (C_{1-3}alkyloxy)-C_{1-3}alkyl; [(C_{1-3}alkyloxy)C_{1-3}alkyloxy]C_{1-3}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; unsubstituted phenyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxyC_{1-3}alkyl, hydroxyC_{1-3}alkyl, cyano, hydroxyl, amino, C(=O)R', C(=O)OR', C(=O)NR'R'', mono- or di(C_{1-3}alkyl)amino, morpholinyl, (C_{3-7}cycloalkyl)C_{1-3}alkyloxy, trifluoromethyl and trifluoromethoxy, wherein R' and R'' are independently selected from hydrogen and C_{1-6}alkyl; (benzyloxy)C_{1-3}alkyl; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with C_{1-3}alkyl substituted with one or more independently selected halo substituents; (C_{3-7}cycloalkyl)C_{1-3}alkyl; [(C_{3-7}cycloalkyl)C_{1-3}alkyloxy]C_{1-3}alkyl; (C_{3-7}cycloalkyl)C_{1-3}alkyloxy; 4-(2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine)methyl; Het^1; Het^1C_{1-3}alkyl; Het^2; and Het^2C_{1-3}alkyl;

R^2 is selected from the group consisting of cyano; halo; C_{1-3}alkyl substituted with one or more independently selected halo substituents; C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; C_{1-3}alkyl; C_{3-7}cycloalkyl; and (C_{3-7}cycloalkyl)C_{1-3}alkyl;


~~(L) is an *N*-containing heterocycle selected from the group consisting of (L-a), (L-b),~~ (L-c), (L-d), (L-e), (L-f), (L-g) and (L-h) below




(L-a)




(L-b)




(L-c)




(L-d)




(L-e)



(L-f)



(L-g)



(L-h)

wherein

R^{3a} is selected from the group consisting of C_{1-3}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with 1 or 2 substituents independently selected from C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents or hydroxyl; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxy-C_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxy substituted with one or more independently selected halo substituents, C_{1-3}alkylcarbonyl, mono- and di(C_{1-3}alkyl)amino, and morpholinyl; unsubstituted (phenyl)C_{1-3}alkyl; (phenyl)C_{1-3}alkyl wherein the phenyl and the C_{1-3}alkyl part of the substituent may each be independently substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxy substituted with one or more independently selected halo substituents, C_{1-3}alkylcarbonyl, mono- or di(C_{1-3}alkyl)amino, morpholinyl and (C_{3-7}cycloalkyl)C_{1-3}alkyloxy; unsubstituted phenyloxy; phenyloxy substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, C_{1-3}alkyloxy, and C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; ~~unsubstituted phenyloxy(C_{1-3}alkyl)oxy; unsubstituted (phenylC_{1-3}alkyl)oxy;~~

phenyl(C_{1-3}alkyl)oxy wherein the phenyl part of the substituent is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, C_{1-3}alkyloxy, and C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; unsubstituted phenyloxyC_{1-3}alkyl; (phenyloxy)C_{1-3}alkyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, C_{1-3}alkyloxy, and C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; unsubstituted phenylamino; phenylamino substituted with 1 or 2 independently selected halo substituents; (phenylC_{1-3}alkyl)amino; (phenylamino)(C_{1-3}alkyl); (C_{3-7}cycloalkyl)C_{1-3}alkyl; [phenyl(C_{3-7}cycloalkyl)]C_{1-3}alkyl; Het^1; Het^2; Het^2oxy; Het^2methyloxy; Het^3; and phenyl with two vicinal substituents which taken together form a bivalent radical of formula


-N=CH-NH- (a),

-CH=CH-NH- (b), or


-O-CH_2-CH_2-NH- (c);

R^{4a} is selected from the group consisting of hydrogen; halogen; trifluoromethyl; trifluoromethoxy; hydroxyl; C_{1-3}alkyl; C_{1-3}alkyloxy; hydroxyC_{1-3}alkyl; hydroxyl-C_{1-3}alkyloxy; fluoroC_{1-3}alkyl; fluoroC_{1-3}alkyloxy; cyano; unsubstituted phenyl; and phenyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C_{1-3}alkyloxy, hydroxyC_{1-3}alkyl, trifluoromethyl and trifluoromethoxy;


or $CR^{3a}R^{4a}$ forms a radical of formula (d), (e), (f), (g) or (h);




(d)




(e)



(f)



(g)



(h)

wherein

each W^{1d}, W^{1e}, W^{2e} and W^{1f} is independently selected from CH and N;

each R^{7d}, R^{7e}, R^{7f}, R^{7g}, R^{8d}, R^{8e}, R^{8f}, R^{8g} is independently selected from hydrogen, methyl and fluoro; or each $CR^{7d}R^{8d}$, $CR^{7e}R^{8e}$, $CR^{7f}R^{8f}$, $CR^{7g}R^{8g}$ form a carbonyl group;

each R^{9d}, R^{9e}, R^{9f}, and R^{9g} is fluoro;

each q1, q2, q3 or q4 is independently selected from 0, 1 and 2;

r is 0 or 1;

s is 0 or 1;


each R^{3b} and R^{3c} is selected from the group consisting of C_{1-3}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxy substituted with one or more independently selected halo substituents, C_{1-3}alkylcarbonyl, mono- and di(C_{1-3}alkyl)amino, and morpholinyl; unsubstituted (phenyl)C_{1-3}alkyl; (phenyl)-C_{1-3}alkyl wherein the phenyl and the C_{1-3}alkyl part of the substituent may each be independently substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxy substituted with one or more independently selected halo substituents, C_{1-3}alkylcarbonyl, mono- or di(C_{1-3}alkyl)amino, morpholinyl, C_{3-7}cycloalkyl, (C_{3-7}cycloalkyl)C_{1-3}alkyl, and (C_{3-7}cycloalkyl)-C_{1-3}alkyloxy; unsubstituted (phenyloxy)C_{1-3}alkyl; (phenyloxy)-C_{1-3}alkyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, C_{1-3}alkyloxy, and C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; (phenylamino)(C_{1-3}alkyl); phenyl with two vicinal substituents which taken together form a bivalent radical of formula (a), (b) or (c) as previously defined; Het^1; Het^2; Het^3; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with 1 or 2 substituents independently selected from C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, or hydroxyl; (C_{3-7}cycloalkyl)C_{1-3}alkyl; and [phenyl-(C_{3-7}cycloalkyl)]C_{1-3}alkyl;


R^{3d} and R^{4d} are each independently selected from the group consisting of hydrogen and C_{1-3}alkyl;

each R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{6a}, R^{6b}, R^{6c} and R^{6d} is independently selected from the group consisting of hydrogen and C_{1-3}alkyl; or each pair $R^{5a}R^{6a}$, $R^{5b}R^{6b}$, $R^{5c}R^{6c}$, $R^{5d}R^{6d}$ are substituents on the same carbon atom and each $CR^{5a}R^{6a}$, $CR^{5b}R^{6b}$, $CR^{5c}R^{6c}$, $CR^{5d}R^{6d}$ together form a (C=O) or a C_{3-7}cycloalkylidene radical;

each R^{10a}, R^{10b} and R^{10c} is selected from H, C_{1-3}alkyl and C_{1-3}alkyloxy;

wherein, in (L-e),
when t is 1 or 2, R^{11} is hydrogen and R^{12} is selected from a substituent selected from the group consisting of phenyl, phenyloxy and phenylamino, each of which may be optionally substituted with 1 or 2 halo substituents; or
when t is 1 or 3, then $CR^{11}R^{12}$ form a radical of formula (i) or formula (j)


(i)


(j)

wherein
each R^{13i} and R^{13j} is independently selected from methyl and trifluoromethyl;
each R^{14i} or R^{14j} is fluoro;
each u1 and u2 is independently 0, 1 or 2;
v1 is selected from the group of 0, 1 and 2;
v2 is selected from the group of 1 and 2;
each z1 and z2 is independently selected from the group of 0, 1 and 2;
each k1 and k2 is independently selected from the group of 0, 1 and 2;

wherein, in (L-f) w is 1 or 2;

wherein in (L-g)
Z is $CR^{16}R^{17}$ and R^{15} is hydrogen when each x is 0 and y is 1; or
Z is $CR^{16}R^{17}$ and R^{15} is selected from the group consisting of hydrogen, methyl and phenyl when each x is 0 and y is 2; or
Z is NR^{16} when each x is 1 and y is 1;

wherein R^{16} and R^{17} are each independently selected from the group consisting of hydrogen; unsubstituted phenyl; and phenyl substituted with 1, 2 or 3 halo substituents;

wherein in (L-h),
Q is O or N-R^{18}, wherein R^{18} is selected from hydrogen and C_{1-3}alkyl;

wherein
each Het^1 is a saturated heterocyclic radical selected from pyrrolidinyl; piperidinyl; piperazinyl; and morpholinyl; each of which may be optionally substituted with 1 or 2 substituents independently selected from the group consisting of C_{1-6}alkyl, halo, C_{1-3}alkyl substituted with one or more independently selected halo substituents, unsubstituted phenyl or phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy; and

each Het^2 is an aromatic heterocyclic radical selected from pyridinyl and pyrimidinyl; each of which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of halo; C_{1-3}alkyl; C_{1-3}alkyloxy; and C_{1-3}alkyl substituted with one or more independently selected halo substituents;

each Het^3 is a heterocyclic radical selected from 1,3-thiazolyl optionally substituted with C_{1-3}alkyl; unsubstituted benzofuranyl; unsubstituted 3,4-dihydro-*2H*-chromenyl; and unsubstituted *1H*-indolyl;

each halo is selected from the group consisting of fluoro, chloro, bromo and iodo;
or a pharmaceutically acceptable salt or a solvate thereof.

2. The compound of formula (I) according to claim 1, or a stereochemically isomeric form thereof, wherein
n is selected from 0 and 1;
m is selected from 0 and 1;
R is methyl;

R^1 is selected from the group consisting of C_{1-6}alkyl; (C_{1-3}alkyloxy)C_{1-3}alkyl; [(C_{1-3}alkyloxy)-C_{1-3}alkyloxy]C_{1-3}alkyl; C_{1-3}alkyl substituted with one or more halo substituents; unsubstituted phenyl; (benzyloxy)C_{1-3}alkyl; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with C_{1-3}alkyl substituted with one or

~~more halo substituents; $(C_{3-7}$cycloalkyl$)C_{1-3}$alkyl; [$(C_{3-7}$cycloalkyl$)C_{1-3}$alkyloxy]~~ C_{1-3}alkyl; $(C_{3-7}$cycloalkyl$)C_{1-3}$alkyloxy; Het^1C_{1-3}alkyl; Het^2; and Het^2C_{1-3}alkyl;

R^2 is selected from the group consisting of cyano; halo; C_{1-3}alkyl substituted with one or more halo substituents; C_{1-3}alkyl; and C_{3-7}cycloalkyl;

(L) is an *N*-containing heterocycle selected from the group consisting of (L-a), (L-b), (L-c), (L-d), (L-e), (L-f), (L-g) and (L-h); wherein

R^{3a} is selected from the group consisting of C_{1-3}alkyl substituted with one or more halo substituents; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more halo substituents, hydroxyl, and C_{1-3}alkyloxy; phenyloxy substituted with 1 or 2 independently selected halo substituents; phenyl(C_{1-3}alkyl)oxy wherein the phenyl part of the substituent is substituted with 1, 2, or 3 independently selected halo substituents; (phenyloxy)C_{1-3}alkyl wherein the phenyl part of the substituent is substituted with 1 or 2 halo substituents; unsubstituted phenylamino; phenylamino substituted with 1 or 2 halo substituents; (phenylC_{1-3}alkyl)amino; Het^1; Het^2; Het^2oxy; Het^2methyloxy; and Het^3;

R^{4a} is selected from the group consisting of hydrogen; halogen; trifluoromethyl; C_{1-3}alkyl; C_{1-3}alkyloxy; and unsubstituted phenyl;

or $CR^{3a}R^{4a}$ forms a radical of formula (d), (e), (f), (g) or (h); wherein

each W^{1d}, W^{1e}, W^{2e} and W^{1f} is independently selected from CH and N;

each R^{7d}, R^{7e}, R^{7f}, R^{7g}, R^{8d}, R^{8e}, R^{8f}, R^{8g} is independently selected from hydrogen, methyl and fluoro; or each $CR^{7d}R^{8d}$, $CR^{7g}R^{8g}$ form a carbonyl group;

each R^{9d}, R^{9e}, R^{9f}, and R^{9g} is fluoro;
each q1, q2, q3 or q4 is independently selected from 0, 1 and 2;
r is 0 or 1;
s is 0 or 1;

each R^{3b} and R^{3c} is selected from the group consisting of C_{1-3}alkyl substituted with one or more halo substituents; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyloxy and C_{1-3}alkyl substituted with one or more halo substituents; unsubstituted (phenyl)C_{1-3}alkyl; (phenyl)C_{1-3}alkyl wherein the phenyl and the C_{1-3}alkyl parts of the substituent may each be independently substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more halo substituents, and (C_{3-7}cycloalkyl)-C_{1-3}alkyloxy; Het^2; Het^3; C_{3-7}cycloalkyl substituted with 1 or 2 substituents independently selected from the group consisting of C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more halo substituents, and hydroxyl; and [phenyl(C_{3-7}cycloalkyl)]C_{1-3}alkyl;

each R^{3d} and R^{4d} is independently selected from hydrogen and C_{1-3}alkyl;

each R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{6a}, R^{6b}, R^{6c} and R^{6d} is independently selected from the group consisting of hydrogen and C_{1-3}alkyl; or $CR^{5b}R^{6b}$ together form a (C=O) or a C_{3-7}cycloalkylidene radical;

each R^{10a}, R^{10b} and R^{10c} is H;

wherein, in (L-e),
when t is 1 or 2, R^{11} is hydrogen and R^{12} is selected from a substituent selected from the group consisting of phenyl, phenyloxy and phenylamino, each of which may be optionally substituted with 1 or 2 halo substituents; or
when t is 1, then $CR^{11}R^{12}$ form a radical of formula (i); wherein
R^{14i} is fluoro;
u1 is 0 or 1;
v1 is 2;
z1 is selected from the group of 1 and 2;
k1 is 0; or
when t is 3, then $CR^{11}R^{12}$ form a radical of formula (i); wherein
R^{14i} is fluoro;
u1 is 0 or 1;
v1 is 0;
z1 is selected from the group of 1 and 2;
k1 is 0;

~~wherein, in (L-f) w is 1 or 2;~~

wherein in (L-g)
Z is $CR^{16}R^{17}$ and R^{15} is hydrogen when each x is 0 and y is 1; or
Z is $CR^{16}R^{17}$ and R^{15} is phenyl when each x is 0 and y is 2; or
Z is NR^{16} when each x is 1 and y is 1;
wherein R^{16} and R^{17} are each independently selected from the group consisting of hydrogen; unsubstituted phenyl; and phenyl substituted with 1, 2 or 3 halo substituents;

wherein in (L-h), Q is O;

each Het^1 is a saturated heterocyclic radical selected from pyrrolidinyl; piperidinyl; piperazinyl; and morpholinyl; each of which is unsubstitued or substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, C_{1-3}alkyl substituted with one or more halo substituents, and unsubstituted phenyl; and

each Het^2 is an aromatic heterocyclic radical selected from pyridinyl and pyrimidinyl; each of which is unsubstituted or substituted with 1 or 2 substituents independently selected from the group consisting of halo; C_{1-3}alkyl; and C_{1-3}alkyloxy;

each Het^3 is a heterocyclic radical selected from 1,3-thiazolyl optionally substituted with C_{1-3}alkyl; unsubstituted benzofuranyl; unsubstituted 3,4-dihydro-*2H*-chromenyl; and unsubstituted *1H*-indolyl;

each halo is selected from the group consisting of fluoro, chloro, and bromo;
or a pharmaceutically acceptable salt or a solvate thereof.

3. The compound according to claim 1, or a stereochemically isomeric form thereof, wherein
n is selected from 0 or 1;
m is 0 or 1;
R is methyl;
R^1 is selected from the group consisting of C_{1-6}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; and (C_{3-7}cycloalkyl)C_{1-3}alkyl;

~~R^2 is selected from halo, C_{1-3}alkyl, and C_{1-3}alkyl substituted with one or more~~ independently selected halo substituents;

L is selected from (L-a) and (L-b); wherein

R^{3a} is selected from the group consisting of unsubstituted phenyl; phenyl substituted with 1 or 2 independently selected halo substituents; pyridinyl; and pyrimidinyl;

R^{4a} is selected from hydrogen; halo and C_{1-3}alkyl;

or $CR^{3a}R^{4a}$ forms a radical of formula (d); wherein

W^{1d} is CH;

R^{7d} and R^{8d} are both methyl;

R^{9d} is fluoro;

q1 is 1;

R^{3b} is phenyl substituted with 1 or 2 halo substituents;

R^{5a}, R^{5b}, R^{6a} and R^{6b} are hydrogen; and

R^{10a} and R^{10b} are hydrogen;


halo is fluoro or chloro;

or a pharmaceutically acceptable salt or a solvate thereof.


4. The compound according to claim 1 or a stereochemically isomeric form thereof wherein

m is 0;

L is selected from the group consisting of (L-a') and (L-b')



(L-a')



(L-b')

R^1 is selected from hydrogen; C_{1-6}alkyl; (C_{1-3}alkyloxy)C_{1-3}alkyl; [(C_{1-3}alkyloxy)-C_{1-3}alkyloxy]C_{1-3}alkyl; mono-, di- or tri-haloC_{1-3}alkyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxyC_{1-3}alkyl, hydroxyC_{1-3}alkyl, cyano, hydroxyl, amino, C(=O)R', C(=O)OR', C(=O)NR'R'', mono- or di(C_{1-3}alkyl)amino, morpholinyl, (C_{3-7}cycloalkyl)C_{1-3}alkyloxy, trifluoromethyl and trifluoromethoxy, wherein R' and R'' are independently selected from hydrogen and C_{1-6}alkyl; ~~(benzyloxy)C_{1-3}alkyl; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with~~

trihaloC$_{1-3}$alkyl; (C$_{3-7}$cycloalkyl)C$_{1-3}$alkyl; 4-(2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine)methyl; Het^1; Het^{1}C$_{1-3}$alkyl; Het^2 and Het^{2}C$_{1-3}$alkyl;

R^2 is selected from cyano; halo; mono-, di- or tri-haloC$_{1-3}$alkyl; mono-, di- and tri-haloC$_{1-3}$alkyloxy; C$_{1-3}$alkyl; C$_{3-7}$cycloalkyl; and (C$_{3-7}$cycloalkyl)C$_{1-3}$alkyl;

R^{3a} and R^{3b} are each selected from unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C$_{1-3}$alkyl, hydroxyC$_{1-3}$alkyl, mono-, di- and tri-haloC$_{1-3}$alkyl, cyano, hydroxyl, amino, carboxyl, C$_{1-3}$alkyloxyC$_{1-3}$alkyl, C$_{1-3}$alkyloxy, mono-, di- or tri-haloC$_{1-3}$alkyloxy, C$_{1-3}$alkylcarbonyl, mono- and di(C$_{1-3}$alkyl)amino, and morpholinyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C$_{1-3}$alkyl, hydroxyC$_{1-3}$alkyl, mono-, di- or tri-haloC$_{1-3}$alkyl, cyano, hydroxyl, amino, carboxyl, C$_{1-3}$alkyloxyC$_{1-3}$alkyl, C$_{1-3}$alkyloxy, mono-, di- and tri-haloC$_{1-3}$alkyloxy, C$_{1-3}$alkylcarbonyl, mono- or di(C$_{1-3}$alkyl)amino, morpholinyl and (C$_{3-7}$cycloalkyl)C$_{1-3}$alkyloxy; phenyl with two vicinal substituents which taken together form a bivalent radical of formula

-N=CH-NH- (a),

-CH=CH-NH- (b), or


-O-CH$_2$-CH$_2$-NH- (c);

morpholinyl; pyridinyl; pyrimidinyl; pyridinyloxy substituted with 1 or 2 C$_{1-3}$alkyl groups; unsubstituted C$_{3-7}$cycloalkyl or C$_{3-7}$cycloalkyl substituted with 1 or 2 substituents independently selected from C$_{1-3}$alkyl, trihaloC$_{1-3}$alkyl or hydroxyl;

R^{4a} is selected from hydrogen; halogen; trifluoromethyl; trifluoromethoxy; hydroxyl; C$_{1-3}$alkyl; C$_{1-3}$alkyloxy; hydroxyC$_{1-3}$alkyl; hydroxyl-C$_{1-3}$alkyloxy; fluoroC$_{1-3}$alkyl; fluoroC$_{1-3}$alkyloxy; cyano; unsubstituted phenyl; or phenyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C$_{1-3}$alkyloxy, hydroxyC$_{1-3}$alkyl, trifluoromethyl and trifluoromethoxy;

or

R^{3a}-C-R^{4a} together represent a radical of formula (d') or (e') or (f') or (g')



(d') (e') (f') (g')

wherein

W^{1d}, W^{1e} and W^{1f} are each selected from CH or N;
R^{7d}, R^{7e}, R^{7f}, R^{8d}, R^{8e} and R^{8f} are each independently selected from hydrogen, methyl or fluoro;
R^{9d}, R^{9e} and R^{9f} are each selected from hydrogen or fluoro;
R^{5a}, R^{5b}, R^{6a} and R^{6b} are each independently selected from the group of hydrogen and C_{1-3}alkyl or $CR^{5a}R^{6a}$ and $CR^{5b}R^{6b}$ together form a C_{3-7}cycloalkyl radical;
n is 0 or 1;

wherein

each Het^1 is a saturated heterocyclic radical selected from pyrrolidinyl; piperidinyl; piperazinyl; and morpholinyl; each of which may be optionally substituted with 1 or 2 substituents independently selected from the group consisting of C_{1-6}alkyl, mono-, di- or tri-haloC_{1-3}alkyl, unsubstituted phenyl and phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy; and

each Het^2 is an aromatic heterocyclic radical selected from unsubstituted pyridinyl and pyrimidinyl;

or a pharmaceutically acceptable salt or a solvate thereof.

5. The compound according to claim 1, including any stereochemically isomeric form thereof, wherein said compound is selected from the group consisting of:
8-chloro-7-(4-fluoro-4-phenyl-1-piperidinyl)-3-(2,2,2-trifluoroethyl)-1,2,4-triazolo-[4,3-a]pyridine;
3-(cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(trifluoromethyl)-1,2,4-triazolo-[4,3-a]pyridine;
3-(cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(trifluoromethyl)-1,2,4-triazolo-[4,3-a]pyridine .1.1HCl;
1'-[3-(cyclopropylmethyl)-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridin-7-yl]-5-fluoro-3,3-dimethyl-spiro[isobenzofuran-1(3H),4'-piperidine],
3-(cyclopropylmethyl)-7-[(4-phenyl-1-piperidinyl)methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine.1.8 HCl,

~~3-(cyclopropylmethyl)-7-[(4-phenyl-1-piperidinyl)methyl]-8-(trifluoromethyl)-1,2,4-~~triazolo[4,3-a]pyridine,
3-(cyclopropylmethyl)-7-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine,
8-chloro-3-(cyclopropylmethyl)-7-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-1,2,4-triazolo[4,3-a]pyridine,
3-(cyclopropylmethyl)-7-[[4-(4-fluorophenyl)-4-methyl-1-piperidinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine, and
3-(cyclopropylmethyl)-7-[(4-fluoro-4-phenyl-1-piperidinyl)methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine,
or a pharmaceutically acceptable salt thereof or a solvate thereof.

6. The compound according to claim 1, including any stereochemically isomeric form thereof, wherein said compound is selected from
3-(cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(trifluoromethyl)-1,2,4-triazolo-[4,3-a]pyridine; and
3-(cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(trifluoromethyl)-1,2,4-triazolo-[4,3-a]pyridine .1.1HCl;
or a pharmaceutically acceptable salt thereof or a solvate thereof.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier or excipient.

8. A compound according to any one of claims 1 to 6 for use as a medicament.

9. A compound according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7 for use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.

10. The compound according to claim 9, for use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety, schizophrenia, migraine, depression, epilepsy, behavioral and psychological symptoms of ~~dementia, major depressive disorder, treatment resistant depression, bipolar~~

depression, generalised anxiety disorder, post-traumatic stress disorder, bipolar mania, substance abuse and mixed anxiety and depression.

11. A compound according to any one of claims 1 to 6 in combination with an orthosteric agonist of mGluR2 for use in the treatment or prevention of a disorder as cited in claim 9 or 10.


12. A process for preparing a pharmaceutical composition as defined in claim 7, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in any one of claims 1 to 6.

13. A product comprising
(a) a compound as defined in any one of claims 1 to 6; and
(b) an mGluR2 orthosteric agonist,
as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.

14. A method of treating or preventing a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia comprising administering to a subject in need thereof a compound according to any one of claims 1 to 6 or a pharmaceutical composition according to claim 7.

CLAIMS

1. A compound of formula (I)



(I)

or a stereochemically isomeric form thereof

wherein

n is selected from the group consisting of 0, 1 and 2;


m is selected from the group consisting of 0, 1, and 2;

R is selected from methyl or trifluoromethyl;


R^1 is selected from the group consisting of hydrogen; C_{1-6}alkyl; (C_{1-3}alkyloxy)-C_{1-3}alkyl; [(C_{1-3}alkyloxy)C_{1-3}alkyloxy]C_{1-3}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; unsubstituted phenyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxyC_{1-3}alkyl, hydroxyC_{1-3}alkyl, cyano, hydroxyl, amino, C(=O)R', C(=O)OR', C(=O)NR'R'', mono- or di(C_{1-3}alkyl)amino, morpholinyl, (C_{3-7}cycloalkyl)C_{1-3}alkyloxy, trifluoromethyl and trifluoromethoxy, wherein R' and R'' are independently selected from hydrogen and C_{1-6}alkyl; (benzyloxy)C_{1-3}alkyl; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with C_{1-3}alkyl substituted with one or more independently selected halo substituents; (C_{3-7}cycloalkyl)C_{1-3}alkyl; [(C_{3-7}cycloalkyl)C_{1-3}alkyloxy]C_{1-3}alkyl; (C_{3-7}cycloalkyl)C_{1-3}alkyloxy; 4-(2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine)methyl; Het^1; Het^1C_{1-3}alkyl; Het^2; and Het^2C_{1-3}alkyl;

R^2 is selected from the group consisting of cyano; halo; C_{1-3}alkyl substituted with one or more independently selected halo substituents; C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; C_{1-3}alkyl; C_{3-7}cycloalkyl; and (C_{3-7}cycloalkyl)C_{1-3}alkyl;


(L) is an *N*-containing heterocycle selected from the group consisting of (L-a), (L-b), (L-c), (L-d), (L-e), (L-f), (L-g) and (L-h) below




(L-a)




(L-b)




(L-c)




(L-d)




(L-e)



(L-f)



(L-g)



(L-h)

wherein

R^{3a} is selected from the group consisting of C_{1-3}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with 1 or 2 substituents independently selected from C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents or hydroxyl; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxy-C_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxy substituted with one or more independently selected halo substituents, C_{1-3}alkylcarbonyl, mono- and di(C_{1-3}alkyl)amino, and morpholinyl; unsubstituted (phenyl)C_{1-3}alkyl; (phenyl)C_{1-3}alkyl wherein the phenyl and the C_{1-3}alkyl part of the substituent may each be independently substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxy substituted with one or more independently selected halo substituents, C_{1-3}alkylcarbonyl, mono- or di(C_{1-3}alkyl)amino, morpholinyl and (C_{3-7}cycloalkyl)C_{1-3}alkyloxy; unsubstituted phenyloxy; phenyloxy substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, C_{1-3}alkyloxy, and C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; unsubstituted phenyloxy(C_{1-3}alkyl)oxy; unsubstituted (phenylC_{1-3}alkyl)oxy; phenyl(C_{1-3}alkyl)oxy wherein the phenyl part of the substituent is substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, C_{1-3}alkyloxy, and C_{1-3}alkyloxy substituted with one or more

independently selected halo substituents; unsubstituted phenyloxyC_{1-3}alkyl; (phenyloxy)C_{1-3}alkyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, C_{1-3}alkyloxy, and C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; unsubstituted phenylamino; phenylamino substituted with 1 or 2 independently selected halo substituents; (phenylC_{1-3}alkyl)amino; (phenylamino)(C_{1-3}alkyl); (C_{3-7}cycloalkyl)C_{1-3}alkyl; [phenyl(C_{3-7}cycloalkyl)]C_{1-3}alkyl; Het^1; Het^2; Het^2oxy; Het^2methyloxy; Het^3; and phenyl with two vicinal substituents which taken together form a bivalent radical of formula


-N=CH-NH- (a),

-CH=CH-NH- (b), or


-O-CH_2-CH_2-NH- (c);

R^{4a} is selected from the group consisting of hydrogen; halogen; trifluoromethyl; trifluoromethoxy; hydroxyl; C_{1-3}alkyl; C_{1-3}alkyloxy; hydroxyC_{1-3}alkyl; hydroxyl-C_{1-3}alkyloxy; fluoroC_{1-3}alkyl; fluoroC_{1-3}alkyloxy; cyano; unsubstituted phenyl; and phenyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C_{1-3}alkyloxy, hydroxyC_{1-3}alkyl, trifluoromethyl and trifluoromethoxy;


or $CR^{3a}R^{4a}$ forms a radical of formula (d), (e), (f), (g) or (h);




(d)




(e)



(f)



(g)



(h)

wherein

each W^{1d}, W^{1e}, W^{2e} and W^{1f} is independently selected from CH and N;

each R^{7d}, R^{7e}, R^{7f}, R^{7g}, R^{8d}, R^{8e}, R^{8f}, R^{8g} is independently selected from hydrogen, methyl and fluoro; or each $CR^{7d}R^{8d}$, $CR^{7e}R^{8e}$, $CR^{7f}R^{8f}$, $CR^{7g}R^{8g}$ form a carbonyl group;

each R^{9d}, R^{9e}, R^{9f}, and R^{9g} is fluoro;

each q1, q2, q3 or q4 is independently selected from 0, 1 and 2;
r is 0 or 1;
s is 0 or 1;


each R^{3b} and R^{3c} is selected from the group consisting of C_{1-3}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxy substituted with one or more independently selected halo substituents, C_{1-3}alkylcarbonyl, mono- and di(C_{1-3}alkyl)amino, and morpholinyl; unsubstituted (phenyl)C_{1-3}alkyl; (phenyl)-C_{1-3}alkyl wherein the phenyl and the C_{1-3}alkyl part of the substituent may each be independently substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxy substituted with one or more independently selected halo substituents, C_{1-3}alkylcarbonyl, mono- or di(C_{1-3}alkyl)amino, morpholinyl, C_{3-7}cycloalkyl, (C_{3-7}cycloalkyl)C_{1-3}alkyl, and (C_{3-7}cycloalkyl)-C_{1-3}alkyloxy; unsubstituted (phenyloxy)C_{1-3}alkyl; (phenyloxy)-C_{1-3}alkyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, C_{1-3}alkyloxy, and C_{1-3}alkyloxy substituted with one or more independently selected halo substituents; (phenylamino)(C_{1-3}alkyl); phenyl with two vicinal substituents which taken together form a bivalent radical of formula (a), (b) or (c) as previously defined; Het^1; Het^2; Het^3; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with 1 or 2 substituents independently selected from C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more independently selected halo substituents, or hydroxyl; (C_{3-7}cycloalkyl)C_{1-3}alkyl; and [phenyl-(C_{3-7}cycloalkyl)]C_{1-3}alkyl;

R^{3d} and R^{4d} are each independently selected from the group consisting of hydrogen and C_{1-3}alkyl;


each R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{6a}, R^{6b}, R^{6c} and R^{6d} is independently selected from the group consisting of hydrogen and C_{1-3}alkyl; or each pair $R^{5a}R^{6a}$, $R^{5b}R^{6b}$, $R^{5c}R^{6c}$, $R^{5d}R^{6d}$ are substituents on the same carbon atom and each $CR^{5a}R^{6a}$, $CR^{5b}R^{6b}$, $CR^{5c}R^{6c}$, $CR^{5d}R^{6d}$ together form a (C=O) or a C_{3-7}cycloalkylidene radical;

each R^{10a}, R^{10b} and R^{10c} is selected from H, C_{1-3}alkyl and C_{1-3}alkyloxy;

wherein, in (L-e),
when t is 1 or 2, R^{11} is hydrogen and R^{12} is selected from a substituent selected from the group consisting of phenyl, phenyloxy and phenylamino, each of which may be optionally substituted with 1 or 2 halo substituents; or
when t is 1 or 3, then $CR^{11}R^{12}$ form a radical of formula (i) or formula (j)



(i)




(j)

wherein
each R^{13i} and R^{13j} is independently selected from methyl and trifluoromethyl;
each R^{14i} or R^{14j} is fluoro;
each u1 and u2 is independently 0, 1 or 2;
v1 is selected from the group of 0, 1 and 2;
v2 is selected from the group of 1 and 2;
each z1 and z2 is independently selected from the group of 0, 1 and 2;
each k1 and k2 is independently selected from the group of 0, 1 and 2;

wherein, in (L-f) w is 1 or 2;

wherein in (L-g)
Z is $CR^{16}R^{17}$ and R^{15} is hydrogen when each x is 0 and y is 1; or
Z is $CR^{16}R^{17}$ and R^{15} is selected from the group consisting of hydrogen, methyl and phenyl when each x is 0 and y is 2; or
(L-g) is (L-g") when Z is NR^{16}



(L-g");

wherein R^{16} and R^{17} are each independently selected from the group consisting of hydrogen; unsubstituted phenyl; and phenyl substituted with 1, 2 or 3 halo substituents;

wherein in (L-h),
Q is O or N-R^{18}, wherein R^{18} is selected from hydrogen and C_{1-3}alkyl;

wherein
each Het^1 is a saturated heterocyclic radical selected from pyrrolidinyl; piperidinyl; piperazinyl; and morpholinyl; each of which may be optionally substituted with 1 or 2 substituents independently selected from the group consisting of C_{1-6}alkyl, halo, C_{1-3}alkyl substituted with one or more independently selected halo substituents, unsubstituted phenyl or phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy; and

each Het^2 is an aromatic heterocyclic radical selected from pyridinyl and pyrimidinyl; each of which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of halo; C_{1-3}alkyl; C_{1-3}alkyloxy; and C_{1-3}alkyl substituted with one or more independently selected halo substituents;

each Het^3 is a heterocyclic radical selected from 1,3-thiazolyl optionally substituted with C_{1-3}alkyl; unsubstituted benzofuranyl; unsubstituted 3,4-dihydro-*2H*-chromenyl; and unsubstituted *1H*-indolyl;

each halo is selected from the group consisting of fluoro, chloro, bromo and iodo;
or a pharmaceutically acceptable salt or a solvate thereof.

2. The compound of formula (I) according to claim 1, or a stereochemically isomeric form thereof, wherein
n is selected from 0 and 1;
m is selected from 0 and 1;
R is methyl;

R^1 is selected from the group consisting of C_{1-6}alkyl; (C_{1-3}alkyloxy)C_{1-3}alkyl; [(C_{1-3}alkyloxy)-C_{1-3}alkyloxy]C_{1-3}alkyl; C_{1-3}alkyl substituted with one or more halo substituents; unsubstituted phenyl; (benzyloxy)C_{1-3}alkyl; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with C_{1-3}alkyl substituted with one or

more halo substituents; (C_{3-7}cycloalkyl)C_{1-3}alkyl; [(C_{3-7}cycloalkyl)C_{1-3}alkyloxy]-C_{1-3}alkyl; (C_{3-7}cycloalkyl)C_{1-3}alkyloxy; Het^1C_{1-3}alkyl; Het^2; and Het^2C_{1-3}alkyl;

R^2 is selected from the group consisting of cyano; halo; C_{1-3}alkyl substituted with one or more halo substituents; C_{1-3}alkyl; and C_{3-7}cycloalkyl;

(L) is an *N*-containing heterocycle selected from the group consisting of (L-a), (L-b), (L-c), (L-d), (L-e), (L-f), (L-g) and (L-h); wherein

R^{3a} is selected from the group consisting of C_{1-3}alkyl substituted with one or more halo substituents; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, hydroxyC_{1-3}alkyl,

C_{1-3}alkyl substituted with one or more halo substituents, hydroxyl, and C_{1-3}alkyloxy; phenyloxy substituted with 1 or 2 independently selected halo substituents; phenyl(C_{1-3}alkyl)oxy wherein the phenyl part of the substituent is substituted with 1, 2, or 3 independently selected halo substituents; (phenyloxy)C_{1-3}alkyl wherein the phenyl part of the substituent is substituted with 1 or 2 halo substituents; unsubstituted phenylamino; phenylamino substituted with 1 or 2 halo substituents; (phenylC_{1-3}alkyl)amino; Het^1; Het^2; Het^2oxy; Het^2methyloxy; and Het^3;

R^{4a} is selected from the group consisting of hydrogen; halogen; trifluoromethyl; C_{1-3}alkyl; C_{1-3}alkyloxy; and unsubstituted phenyl;

or $CR^{3a}R^{4a}$ forms a radical of formula (d), (e), (f), (g) or (h); wherein

each W^{1d}, W^{1e}, W^{2e} and W^{1f} is independently selected from CH and N;

each R^{7d}, R^{7e}, R^{7f}, R^{7g}, R^{8d}, R^{8e}, R^{8f}, R^{8g} is independently selected from hydrogen, methyl and fluoro; or each $CR^{7d}R^{8d}$, $CR^{7g}R^{8g}$ form a carbonyl group;

each R^{9d}, R^{9e}, R^{9f}, and R^{9g} is fluoro;
each q1, q2, q3 or q4 is independently selected from 0, 1 and 2;
r is 0 or 1;
s is 0 or 1;

each R^{3b} and R^{3c} is selected from the group consisting of C_{1-3}alkyl substituted with one or more halo substituents; unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyloxy and C_{1-3}alkyl substituted with one or more halo substituents; unsubstituted (phenyl)C_{1-3}alkyl; (phenyl)C_{1-3}alkyl wherein the phenyl and the C_{1-3}alkyl parts of the substituent may each be independently substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more halo substituents, and (C_{3-7}cycloalkyl)-C_{1-3}alkyloxy; Het^2; Het^3; C_{3-7}cycloalkyl substituted with 1 or 2 substituents independently selected from the group consisting of C_{1-3}alkyl, C_{1-3}alkyl substituted with one or more halo substituents, and hydroxyl; and [phenyl(C_{3-7}cycloalkyl)]C_{1-3}alkyl;

each R^{3d} and R^{4d} is independently selected from hydrogen and C_{1-3}alkyl;


each R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{6a}, R^{6b}, R^{6c} and R^{6d} is independently selected from the group consisting of hydrogen and C_{1-3}alkyl; or $CR^{5b}R^{6b}$ together form a (C=O) or a C_{3-7}cycloalkylidene radical;

each R^{10a}, R^{10b} and R^{10c} is H;

wherein, in (L-e),
when t is 1 or 2, R^{11} is hydrogen and R^{12} is selected from a substituent selected from the group consisting of phenyl, phenyloxy and phenylamino, each of which may be optionally substituted with 1 or 2 halo substituents; or
when t is 1, then $CR^{11}R^{12}$ form a radical of formula (i); wherein
R^{14i} is fluoro;
u1 is 0 or 1;
v1 is 2;
z1 is selected from the group of 1 and 2;
k1 is 0; or
when t is 3, then $CR^{11}R^{12}$ form a radical of formula (i); wherein
R^{14i} is fluoro;
u1 is 0 or 1;
v1 is 0;
z1 is selected from the group of 1 and 2;
k1 is 0;

wherein, in (L-f) w is 1 or 2;

wherein in (L-g)
Z is $CR^{16}R^{17}$ and R^{15} is hydrogen when each x is 0 and y is 1; or
Z is $CR^{16}R^{17}$ and R^{15} is phenyl when each x is 0 and y is 2; or
(L-g) is (L-g") when Z is NR^{16}



(L-g");

wherein R^{16} and R^{17} are each independently selected from the group consisting of hydrogen; unsubstituted phenyl; and phenyl substituted with 1, 2 or 3 halo substituents;

wherein in (L-h), Q is O;

each Het^1 is a saturated heterocyclic radical selected from pyrrolidinyl; piperidinyl; piperazinyl; and morpholinyl; each of which is unsubstitued or substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, C_{1-3}alkyl substituted with one or more halo substituents, and unsubstituted phenyl; and

each Het^2 is an aromatic heterocyclic radical selected from pyridinyl and pyrimidinyl; each of which is unsubstituted or substituted with 1 or 2 substituents selected from the group consisting of halo; C_{1-3}alkyl; and C_{1-3}alkyloxy;

each Het^3 is a heterocyclic radical selected from 1,3-thiazolyl optionally substituted with C_{1-3}alkyl; unsubstituted benzofuranyl; unsubstituted 3,4-dihydro-*2H*-chromenyl; and unsubstituted *1H*-indolyl;

each halo is selected from the group consisting of fluoro, chloro, and bromo;
or a pharmaceutically acceptable salt or a solvate thereof.

3. The compound according to claim 1, or a stereochemically isomeric form thereof, wherein
n is selected from 0 or 1;
m is 0 or 1;
R is methyl;

R^1 is selected from the group consisting of C_{1-6}alkyl; C_{1-3}alkyl substituted with one or more independently selected halo substituents; and (C_{3-7}cycloalkyl)C_{1-3}alkyl;

R^2 is selected from halo, C_{1-3}alkyl, and C_{1-3}alkyl substituted with one or more independently selected halo substituents;

(L) is selected from (L-a) and (L-b); wherein

R^{3a} is selected from the group consisting of unsubstituted phenyl; phenyl substituted with 1 or 2 independently selected halo substituents; pyridinyl; and pyrimidinyl;

R^{4a} is selected from hydrogen; halo and C_{1-3}alkyl;

or $CR^{3a}R^{4a}$ forms a radical of formula (d); wherein

W^{1d} is CH;

R^{7d} and R^{8d} are both methyl;

R^{9d} is fluoro;

q1 is 1;

R^{3b} is phenyl substituted with 1 or 2 halo substituents;

R^{5a}, R^{5b}, R^{6a} and R^{6b} are hydrogen; and


R^{10a} and R^{10b} are hydrogen;

halo is fluoro or chloro;


or a pharmaceutically acceptable salt or a solvate thereof.

4. The compound according to claim 1 or a stereochemically isomeric form thereof wherein

(L) is an *N*-containing heterocycle selected from the group consisting of



(L-a')



(L-b')

and the stereochemically isomeric forms thereof, wherein

R^1 is selected from hydrogen; C_{1-6}alkyl; (C_{1-3}alkyloxy)C_{1-3}alkyl; [(C_{1-3}alkyloxy)-C_{1-3}alkyloxy]C_{1-3}alkyl; mono-, di- or tri-haloC_{1-3}alkyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, C_{1-3}alkyloxy, C_{1-3}alkyloxyC_{1-3}alkyl, hydroxyC_{1-3}alkyl, cyano, hydroxyl, amino, C(=O)R', C(=O)OR', C(=O)NR'R'', mono- or di(C_{1-3}alkyl)amino, morpholinyl, (C_{3-7}cycloalkyl)C_{1-3}alkyloxy, trifluoromethyl and trifluoromethoxy, wherein R' and R'' are independently selected from hydrogen and

C_{1-6}alkyl; (benzyloxy)C_{1-3}alkyl; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with trihaloC_{1-3}alkyl; (C_{3-7}cycloalkyl)C_{1-3}alkyl; 4-(2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine)methyl; Het^1; Het^1C_{1-3}alkyl; Het^2 and Het^2C_{1-3}alkyl;

R^2 is selected from cyano; halo; mono-, di- or tri-haloC_{1-3}alkyl; mono-, di- and tri-haloC_{1-3}alkyloxy; C_{1-3}alkyl; C_{3-7}cycloalkyl; and (C_{3-7}cycloalkyl)C_{1-3}alkyl;

R^{3a} is selected from unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, mono-, di- and tri-haloC_{1-3}alkyl, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, mono-, di- or tri-haloC_{1-3}alkyloxy, C_{1-3}alkylcarbonyl, mono- and di(C_{1-3}alkyl)amino, and morpholinyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, mono-, di- or tri-haloC_{1-3}alkyl, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, mono-, di- and tri-haloC_{1-3}alkyloxy, C_{1-3}alkylcarbonyl, mono- or di(C_{1-3}alkyl)amino, morpholinyl and (C_{3-7}cycloalkyl)C_{1-3}alkyloxy; phenyl with two vicinal substituents which taken together form a bivalent radical of formula

-N=CH-NH- (a),

-CH=CH-NH- (b), or

-O-CH_2-CH_2-NH- (c);

morpholinyl; pyridinyl; pyrimidinyl; pyridinyloxy substituted with 1 or 2 C_{1-3}alkyl groups; unsubstituted C_{3-7}cycloalkyl and C_{3-7}cycloalkyl substituted with 1 or 2 substituents independently selected from C_{1-3}alkyl, trihaloC_{1-3}alkyl and hydroxyl;

R^{3b} is selected from unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, mono-, di- and tri-haloC_{1-3}alkyl, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, mono-, di- or tri-haloC_{1-3}alkyloxy, C_{1-3}alkylcarbonyl, mono- and di(C_{1-3}alkyl)amino, and morpholinyl; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, C_{1-3}alkyl, hydroxyC_{1-3}alkyl, mono-, di- or tri-haloC_{1-3}alkyl, cyano, hydroxyl, amino, carboxyl, C_{1-3}alkyloxyC_{1-3}alkyl, C_{1-3}alkyloxy, mono-, di- and tri-haloC_{1-3}alkyloxy, C_{1-3}alkylcarbonyl, mono- or di(C_{1-3}alkyl)amino, morpholinyl and (C_{3-7}cycloalkyl)C_{1-3}alkyloxy; phenyl with two vicinal substituents which taken together form a bivalent radical of formula

-N=CH-NH- (a),

-CH=CH-NH- (b), or


-O-CH_2-CH_2-NH- (c);

pyridinyl; pyrimidinyl; unsubstituted C_{3-7}cycloalkyl and C_{3-7}cycloalkyl substituted with 1 or 2 substituents independently selected from C_{1-3}alkyl, trihaloC_{1-3}alkyl and hydroxyl;


R^{4a} is selected from hydrogen; halogen; trifluoromethyl; trifluoromethoxy; hydroxyl; C_{1-3}alkyl; C_{1-3}alkyloxy; hydroxyC_{1-3}alkyl; hydroxylC_{1-3}alkyloxy; fluoroC_{1-3}alkyl; fluoroC_{1-3}alkyloxy; cyano; unsubstituted phenyl; and phenyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C_{1-3}alkyloxy, hydroxyC_{1-3}alkyl, trifluoromethyl and trifluoromethoxy;

or


R^{3a}-C-R^{4a} together represent a radical of formula (d') or (e') or (f') or (g')




(d')



(e')



(f')



(g')

wherein

W^{1d}, W^{1e} and W^{1f} are each selected from CH or N;

R^{7d}, R^{7e}, R^{7f}, R^{8d}, R^{8e} and R^{8f} are each independently selected from hydrogen, methyl or fluoro;

R^{9d}, R^{9e} and R^{9f} are each selected from hydrogen and fluoro;

R^{5a}, R^{5b}, R^{6a} and R^{6b} are each independently selected from the group of hydrogen and C_{1-3}alkyl or $CR^{5a}R^{6a}$ and $CR^{5b}R^{6b}$ together form a C_{3-7}cycloalkyl radical;

n is 0 or 1;

wherein

each Het^1 is a saturated heterocyclic radical selected from pyrrolidinyl; piperidinyl; piperazinyl; and morpholinyl; each of which may be optionally substituted with 1 or 2 substituents independently selected from the group consisting of C_{1-6}alkyl, mono-, di- and tri-haloC_{1-3}alkyl, unsubstituted phenyl, and phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, trifluoromethyl, and trifluoromethoxy; and

each Het^2 is an aromatic heterocyclic radical selected from unsubstituted pyridinyl and pyrimidinyl;

or a pharmaceutically acceptable salt or a solvate thereof.


5. The compound according to claim 4 or a stereochemically isomeric form thereof wherein

R^1 is selected from C_{1-6}alkyl; (C_{1-3}alkyloxy)C_{1-3}alkyl; [(C_{1-3}alkyloxy)C_{1-3}alkyloxy]-C_{1-3}alkyl; mono-, di- and tri-haloC_{1-3}alkyl; (benzyloxy)C_{1-3}alkyl; unsubstituted C_{3-7}cycloalkyl; C_{3-7}cycloalkyl substituted with trihaloC_{1-3}alkyl; (C_{3-7}cycloalkyl)-C_{1-3}alkyl; 4-(2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine)methyl; Het^1; and Het^1C_{1-3}alkyl;


R^2 is cyano; halo or tri-haloC_{1-3}alkyl;

R^{3a} and R^{3b} are each selected from unsubstituted phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from the group consisting of halo, hydroxyl-C_{1-3}alkyl, mono-, di- and tri-haloC_{1-3}alkyl, hydroxyl and C_{1-3}alkyloxy; unsubstituted benzyl; benzyl substituted with 1, 2 or 3 substituents independently selected from halo, mono-, di- or tri-haloC_{1-3}alkyl, and (C_{3-7}cycloalkyl)C_{1-3}alkyloxy; pyridinyl; pyrimidinyl; and
C_{3-7}cycloalkyl substituted with 1 or 2 substituents selected from C_{1-3}alkyl, trihaloC_{1-3}alkyl and hydroxyl;


R^{4a} is selected from hydrogen; halogen; trifluoromethyl; unsubstituted phenyl; and phenyl substituted with 1 or 2 substituents independently selected from the group consisting of halo, C_{1-3}alkyloxy, hydroxyC_{1-3}alkyl, trifluoromethyl and trifluoromethoxy;
or
R^{3a}-C-R^{4a} together represent a radical of formula (d) or (e) or (f) or (g)




(d')



(e')



(f')



(g')

wherein

W^{1d}, W^{1e} and W^{1f} are each selected from CH and N;

n is 0 or 1;


R^{5a}, R^{5b}, R^{6a} and R^{6b} are each independently selected from the group of hydrogen and C_{1-3}alkyl;

R^{7d}, R^{7e}, R^{7f}, R^{8d}, R^{8e}, R^{8f}, R^{9d}, R^{9e}, R^{9f} and Het^1 are as defined in claim 4;

or a pharmaceutically acceptable salt or a solvate thereof.

6. The compound according to claim 1, wherein said compound is selected from the group consisting of:
8-chloro-7-(4-fluoro-4-phenyl-1-piperidinyl)-3-(2,2,2-trifluoroethyl)-1,2,4-triazolo-[4,3-a]pyridine;
3-(cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(trifluoromethyl)-1,2,4-triazolo-[4,3-a]pyridine;
3-(cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(trifluoromethyl)-1,2,4-triazolo-[4,3-a]pyridine .1.1HCl;
1'-[3-(cyclopropylmethyl)-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridin-7-yl]-5-fluoro-3,3-dimethyl-spiro[isobenzofuran-1(3H),4'-piperidine],
3-(cyclopropylmethyl)-7-[(4-phenyl-1-piperidinyl)methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine.1.8 HCl,
3-(cyclopropylmethyl)-7-[(4-phenyl-1-piperidinyl)methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine,
3-(cyclopropylmethyl)-7-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine,
8-chloro-3-(cyclopropylmethyl)-7-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-1,2,4-triazolo[4,3-a]pyridine,
3-(cyclopropylmethyl)-7-[[4-(4-fluorophenyl)-4-methyl-1-piperidinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine, and
3-(cyclopropylmethyl)-7-[(4-fluoro-4-phenyl-1-piperidinyl)methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine,
or a pharmaceutically acceptable salt thereof or a solvate thereof.


7. The compound according to claim 1, wherein said compound is



3-(cyclopropylmethyl)-7-[[4-(2,4-difluorophenyl)-1-piperazinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine

or a pharmaceutically acceptable salt thereof or a solvate thereof.


8. The compound according to claim 1, wherein said compound is




3-(cyclopropylmethyl)-7-[4-(5-methoxy-2-pyrimidinyl)-1-piperazinyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine

or a pharmaceutically acceptable salt thereof or a solvate thereof.


9. The compound according to claim 1, wherein said compound is selected from



8-chloro-3-(cyclopropylmethyl)-7-[4-(2,4-difluorophenyl)-1-piperidinyl]-1,2,4-triazolo[4,3-a]pyridine



3-(cyclopropylmethyl)-7-[4-(2-pyrimidinyl)-1-piperazinyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine



1'-[8-chloro-3-(2,2,2-trifluoroethyl)-1,2,4-triazolo[4,3-a]pyridin-7-yl]-3,3-dimethyl-spiro[isobenzofuran-1(3H),4'-piperidine]

or a pharmaceutically acceptable salt thereof or a solvate thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier or excipient.

11. A compound according to any one of claims 1 to 9 for use as a medicament.

12. A compound according to any one of claims 1 to 9 or a pharmaceutical composition according to claim 10 for use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.

13. The compound according to any one of claims 1 to 9, for use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety, schizophrenia, migraine, depression, epilepsy, behavioral and psychological symptoms of dementia, major depressive disorder, treatment resistant depression, bipolar depression, generalised anxiety disorder, post-traumatic stress disorder, bipolar mania, substance abuse and mixed anxiety and depression.

14. A compound according to any one of claims 1 to 9 in combination with an orthosteric agonist of mGluR2 for use in the treatment or prevention of a disorder as cited in claim 12 or 13.

15. A process for preparing a pharmaceutical composition as defined in claim 10, characterized in that a pharmaceutically acceptable carrier is intimately mixed

with a therapeutically effective amount of a compound as defined in any one of claims 1 to 9.

16. A product comprising

(a) a compound as defined in any one of claims 1 to 9; and

(b) an mGluR2 orthosteric agonist,

as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.